California 2021-2022 Regular Session

California Assembly Bill AB2265 Compare Versions

OldNewDifferences
1-Amended IN Assembly April 06, 2022 Amended IN Assembly March 30, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 2265Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)February 16, 2022 An act to add Article 12.5 (commencing with Section 4178) to Chapter 9 of Division 2 of the Business and Professions Code, relating to healing arts. LEGISLATIVE COUNSEL'S DIGESTAB 2265, as amended, Arambula. Pharmacy: dispensing controlled substances: lockable vials.Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy. The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, vial and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. rendered. The bill would require the board, by October 1, 2023, to establish reasonable minimum and maximum amounts of reimbursement that include the cost of the lockable vial and services rendered and dispensing costs. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. (a) The Legislature finds and declares as follows:(a)(1) The federal Poison Prevention Packaging Act of 1970 (PPPA) requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b)(2) After the PPPA was implemented, deaths in children five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c)(3) Pilfering is the leading source of youth opioid abuse.(d)(4) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e)(5) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f)(6) During the first year of the pandemic, opioid abuse in California rose 44.6 percent while in the nation as a whole it rose 30 percent.(g)(7) Locking pill vials have been shown to reduce or eliminate pilfering.(h)(8) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i)(9) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. (b) It is therefore the intent of the Legislature in enacting this act to do all of the following:(1) Expand safety precautions for the administration of controlled substances in Schedule II and Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).(2) Require a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act to dispense the substance in a lockable vial, except as specified.(3) Require the manufacturer of a controlled substance covered by this act to reimburse a pharmacy for the cost of the vial and services rendered and dispensing costs.(4) Require the California State Board of Pharmacy to establish reasonable minimum and maximum amounts of reimbursement to a pharmacy for the cost of the vial and services rendered and dispensing costs.(5) Ensure that the cost of administering controlled substances in lockable vials does not increase costs to patients and insurers.SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
1+Amended IN Assembly March 30, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 2265Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)February 16, 2022 An act to add Article 12.5 (commencing with Section 4178) to Chapter 9 of Division 2 of the Business and Professions Code, relating to healing arts. LEGISLATIVE COUNSEL'S DIGESTAB 2265, as amended, Arambula. Pharmacy: dispensing controlled substances: lockable vials.Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet, and to include the passcode, if any, for the lockable vial in the database or other system used by the pharmacy in the dispensing of prescription drugs. factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy.This The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy.This bill would require a vendor that contracts with a pharmacy to provide lockable vials to make available at all times assistance online or through a toll-free phone number for patient use. pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship.This hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. The Legislature finds and declares as follows:(a) The federal Poison Prevention Packaging Act of 1970 (PPPA) required requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b) After the PPPA was implemented, deaths in children 5 five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c) Pilfering is the leading source of youth opioid abuse.(d) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f) During the pandemic year, first year of the pandemic, opioid abuse in California is up rose 44.6 percent while in the nation as a whole it is up rose 30 percent.(g) Locking pill vials have been shown to reduce or eliminate pilfering.(h) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
22
3- Amended IN Assembly April 06, 2022 Amended IN Assembly March 30, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 2265Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)February 16, 2022 An act to add Article 12.5 (commencing with Section 4178) to Chapter 9 of Division 2 of the Business and Professions Code, relating to healing arts. LEGISLATIVE COUNSEL'S DIGESTAB 2265, as amended, Arambula. Pharmacy: dispensing controlled substances: lockable vials.Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy. The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, vial and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. rendered. The bill would require the board, by October 1, 2023, to establish reasonable minimum and maximum amounts of reimbursement that include the cost of the lockable vial and services rendered and dispensing costs. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
3+ Amended IN Assembly March 30, 2022 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION Assembly Bill No. 2265Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)February 16, 2022 An act to add Article 12.5 (commencing with Section 4178) to Chapter 9 of Division 2 of the Business and Professions Code, relating to healing arts. LEGISLATIVE COUNSEL'S DIGESTAB 2265, as amended, Arambula. Pharmacy: dispensing controlled substances: lockable vials.Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet, and to include the passcode, if any, for the lockable vial in the database or other system used by the pharmacy in the dispensing of prescription drugs. factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy.This The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy.This bill would require a vendor that contracts with a pharmacy to provide lockable vials to make available at all times assistance online or through a toll-free phone number for patient use. pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship.This hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
44
5- Amended IN Assembly April 06, 2022 Amended IN Assembly March 30, 2022
5+ Amended IN Assembly March 30, 2022
66
7-Amended IN Assembly April 06, 2022
87 Amended IN Assembly March 30, 2022
98
109 CALIFORNIA LEGISLATURE 20212022 REGULAR SESSION
1110
1211 Assembly Bill
1312
1413 No. 2265
1514
1615 Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)February 16, 2022
1716
1817 Introduced by Assembly Member Arambula(Principal coauthor: Senator Umberg)
1918 February 16, 2022
2019
2120 An act to add Article 12.5 (commencing with Section 4178) to Chapter 9 of Division 2 of the Business and Professions Code, relating to healing arts.
2221
2322 LEGISLATIVE COUNSEL'S DIGEST
2423
2524 ## LEGISLATIVE COUNSEL'S DIGEST
2625
2726 AB 2265, as amended, Arambula. Pharmacy: dispensing controlled substances: lockable vials.
2827
29-Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy. The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, vial and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. rendered. The bill would require the board, by October 1, 2023, to establish reasonable minimum and maximum amounts of reimbursement that include the cost of the lockable vial and services rendered and dispensing costs. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.
28+Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet, and to include the passcode, if any, for the lockable vial in the database or other system used by the pharmacy in the dispensing of prescription drugs. factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy.This The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy.This bill would require a vendor that contracts with a pharmacy to provide lockable vials to make available at all times assistance online or through a toll-free phone number for patient use. pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction. This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship.This hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.
3029
3130 Existing law, the Pharmacy Law, provides for the licensing and regulation of pharmacists by the California State Board of Pharmacy in the Department of Consumer Affairs. Existing law prohibits a person from possessing any controlled substance, with certain exceptions, including substances furnished to a person upon the prescription of a physician, dentist, podiatrist, optometrist, veterinarian, or another of specified healing arts licensees.
3231
33-This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy. The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, vial and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. rendered. The bill would require the board, by October 1, 2023, to establish reasonable minimum and maximum amounts of reimbursement that include the cost of the lockable vial and services rendered and dispensing costs. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.
32+This bill would, commencing June 30, 2023, require a pharmacist, with certain exceptions, to dispense a Schedule II or Schedule IIN controlled substance in a lockable vial, as defined. The bill would require the pharmacist to also provide to a patient a specified opioid factsheet, and to include the passcode, if any, for the lockable vial in the database or other system used by the pharmacy in the dispensing of prescription drugs. factsheet and the lockable vial vendors online assistance information or toll-free telephone number, which a vendor contracting with a pharmacy would be required to provide to the pharmacy.
33+
34+This The bill would require the manufacturer of the controlled substance to reimburse the pharmacy within 30 days of receiving the pharmacys claim for reimbursement for the cost of the lockable vial, not to exceed $2 per vial, and for the pharmacys dispensing costs and services rendered, not to exceed $2.50 per vial. The bill would make the manufacturer of a controlled substance subject to a civil penalty of $1,000 for each day the manufacturer is delinquent in reimbursing the pharmacy.
35+
36+This bill would require a vendor that contracts with a pharmacy to provide lockable vials to make available at all times assistance online or through a toll-free phone number for patient use. pharmacy. The bill would, with certain exceptions, grant prescribers and pharmacists immunity from liability for adverse consequences resulting from a patient not being able to access their medication in a lockable vial or the failure of the lockable vial to prevent unauthorized access.
3437
3538 Existing law, when no other penalty is provided, makes a knowing violation of the Pharmacy Law a misdemeanor and, in all other instances, makes a violation punishable as an infraction.
3639
37- This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions. The bill would provide related findings and declarations of the Legislature.
40+ This bill would exempt violations of the bills provisions from those criminal penalties. The bill would require the board to assess an unspecified fine, to be determined by the board, for a violation of the bills provisions by a pharmacist and would authorize the board to refrain from taking administrative action under certain circumstances, including a finding of financial hardship.
41+
42+This hardship. The bill would exempt correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation from the bill, and would authorize the board to adopt regulations to carry out its provisions.
43+
44+The bill would provide related findings and declarations of the Legislature.
3845
3946 ## Digest Key
4047
4148 ## Bill Text
4249
43-The people of the State of California do enact as follows:SECTION 1. (a) The Legislature finds and declares as follows:(a)(1) The federal Poison Prevention Packaging Act of 1970 (PPPA) requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b)(2) After the PPPA was implemented, deaths in children five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c)(3) Pilfering is the leading source of youth opioid abuse.(d)(4) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e)(5) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f)(6) During the first year of the pandemic, opioid abuse in California rose 44.6 percent while in the nation as a whole it rose 30 percent.(g)(7) Locking pill vials have been shown to reduce or eliminate pilfering.(h)(8) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i)(9) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. (b) It is therefore the intent of the Legislature in enacting this act to do all of the following:(1) Expand safety precautions for the administration of controlled substances in Schedule II and Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).(2) Require a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act to dispense the substance in a lockable vial, except as specified.(3) Require the manufacturer of a controlled substance covered by this act to reimburse a pharmacy for the cost of the vial and services rendered and dispensing costs.(4) Require the California State Board of Pharmacy to establish reasonable minimum and maximum amounts of reimbursement to a pharmacy for the cost of the vial and services rendered and dispensing costs.(5) Ensure that the cost of administering controlled substances in lockable vials does not increase costs to patients and insurers.SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
50+The people of the State of California do enact as follows:SECTION 1. The Legislature finds and declares as follows:(a) The federal Poison Prevention Packaging Act of 1970 (PPPA) required requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b) After the PPPA was implemented, deaths in children 5 five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c) Pilfering is the leading source of youth opioid abuse.(d) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f) During the pandemic year, first year of the pandemic, opioid abuse in California is up rose 44.6 percent while in the nation as a whole it is up rose 30 percent.(g) Locking pill vials have been shown to reduce or eliminate pilfering.(h) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
4451
4552 The people of the State of California do enact as follows:
4653
4754 ## The people of the State of California do enact as follows:
4855
49-SECTION 1. (a) The Legislature finds and declares as follows:(a)(1) The federal Poison Prevention Packaging Act of 1970 (PPPA) requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b)(2) After the PPPA was implemented, deaths in children five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c)(3) Pilfering is the leading source of youth opioid abuse.(d)(4) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e)(5) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f)(6) During the first year of the pandemic, opioid abuse in California rose 44.6 percent while in the nation as a whole it rose 30 percent.(g)(7) Locking pill vials have been shown to reduce or eliminate pilfering.(h)(8) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i)(9) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. (b) It is therefore the intent of the Legislature in enacting this act to do all of the following:(1) Expand safety precautions for the administration of controlled substances in Schedule II and Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).(2) Require a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act to dispense the substance in a lockable vial, except as specified.(3) Require the manufacturer of a controlled substance covered by this act to reimburse a pharmacy for the cost of the vial and services rendered and dispensing costs.(4) Require the California State Board of Pharmacy to establish reasonable minimum and maximum amounts of reimbursement to a pharmacy for the cost of the vial and services rendered and dispensing costs.(5) Ensure that the cost of administering controlled substances in lockable vials does not increase costs to patients and insurers.
56+SECTION 1. The Legislature finds and declares as follows:(a) The federal Poison Prevention Packaging Act of 1970 (PPPA) required requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b) After the PPPA was implemented, deaths in children 5 five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c) Pilfering is the leading source of youth opioid abuse.(d) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f) During the pandemic year, first year of the pandemic, opioid abuse in California is up rose 44.6 percent while in the nation as a whole it is up rose 30 percent.(g) Locking pill vials have been shown to reduce or eliminate pilfering.(h) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent.
5057
51-SECTION 1. (a) The Legislature finds and declares as follows:(a)(1) The federal Poison Prevention Packaging Act of 1970 (PPPA) requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b)(2) After the PPPA was implemented, deaths in children five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c)(3) Pilfering is the leading source of youth opioid abuse.(d)(4) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e)(5) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f)(6) During the first year of the pandemic, opioid abuse in California rose 44.6 percent while in the nation as a whole it rose 30 percent.(g)(7) Locking pill vials have been shown to reduce or eliminate pilfering.(h)(8) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i)(9) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent. (b) It is therefore the intent of the Legislature in enacting this act to do all of the following:(1) Expand safety precautions for the administration of controlled substances in Schedule II and Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).(2) Require a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act to dispense the substance in a lockable vial, except as specified.(3) Require the manufacturer of a controlled substance covered by this act to reimburse a pharmacy for the cost of the vial and services rendered and dispensing costs.(4) Require the California State Board of Pharmacy to establish reasonable minimum and maximum amounts of reimbursement to a pharmacy for the cost of the vial and services rendered and dispensing costs.(5) Ensure that the cost of administering controlled substances in lockable vials does not increase costs to patients and insurers.
58+SECTION 1. The Legislature finds and declares as follows:(a) The federal Poison Prevention Packaging Act of 1970 (PPPA) required requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.(b) After the PPPA was implemented, deaths in children 5 five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.(c) Pilfering is the leading source of youth opioid abuse.(d) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.(e) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.(f) During the pandemic year, first year of the pandemic, opioid abuse in California is up rose 44.6 percent while in the nation as a whole it is up rose 30 percent.(g) Locking pill vials have been shown to reduce or eliminate pilfering.(h) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.(i) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent.
5259
53-SECTION 1. (a) The Legislature finds and declares as follows:
60+SECTION 1. The Legislature finds and declares as follows:
5461
5562 ### SECTION 1.
5663
57-(a)
64+(a) The federal Poison Prevention Packaging Act of 1970 (PPPA) required requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.
5865
66+(b) After the PPPA was implemented, deaths in children 5 five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.
5967
68+(c) Pilfering is the leading source of youth opioid abuse.
6069
61-(1) The federal Poison Prevention Packaging Act of 1970 (PPPA) requires child resistant caps for prescription medications, and these requirements have not been updated in the subsequent 50 years.
70+(d) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.
6271
63-(b)
72+(e) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.
6473
74+(f) During the pandemic year, first year of the pandemic, opioid abuse in California is up rose 44.6 percent while in the nation as a whole it is up rose 30 percent.
6575
76+(g) Locking pill vials have been shown to reduce or eliminate pilfering.
6677
67-(2) After the PPPA was implemented, deaths in children five years of age and younger went down by 1.4 per million. This represented a reduction in the rate of fatalities, up to 45 percent, from projections of deaths without the presence of childproof packaging.
78+(h) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.
6879
69-(c)
80+(i) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent.
7081
71-
72-
73-(3) Pilfering is the leading source of youth opioid abuse.
74-
75-(d)
76-
77-
78-
79-(4) Each year, nearly 600,000 children between 12 and 17 years of age initiate prescription drug abuse by pilfering medication from an adult in their home.
80-
81-(e)
82-
83-
84-
85-(5) Between 1999 and 2016, prescription and illicit drug poisonings saw an increased mortality rate of 268 percent.
86-
87-(f)
88-
89-
90-
91-(6) During the first year of the pandemic, opioid abuse in California rose 44.6 percent while in the nation as a whole it rose 30 percent.
92-
93-(g)
94-
95-
96-
97-(7) Locking pill vials have been shown to reduce or eliminate pilfering.
98-
99-(h)
100-
101-
102-
103-(8) Locking pill vials are inexpensive, costing less than $2 each, and the costs are expected to come down significantly.
104-
105-(i)
106-
107-
108-
109-(9) Long-term return on investment of locking pill vials in saved medical costs is anticipated to be over 80 percent.
110-
111-(b) It is therefore the intent of the Legislature in enacting this act to do all of the following:
112-
113-(1) Expand safety precautions for the administration of controlled substances in Schedule II and Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.).
114-
115-(2) Require a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act to dispense the substance in a lockable vial, except as specified.
116-
117-(3) Require the manufacturer of a controlled substance covered by this act to reimburse a pharmacy for the cost of the vial and services rendered and dispensing costs.
118-
119-(4) Require the California State Board of Pharmacy to establish reasonable minimum and maximum amounts of reimbursement to a pharmacy for the cost of the vial and services rendered and dispensing costs.
120-
121-(5) Ensure that the cost of administering controlled substances in lockable vials does not increase costs to patients and insurers.
122-
123-SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
82+SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read: Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
12483
12584 SEC. 2. Article 12.5 (commencing with Section 4178) is added to Chapter 9 of Division 2 of the Business and Professions Code, to read:
12685
12786 ### SEC. 2.
12887
129- Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
88+ Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
13089
131- Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
90+ Article 12.5. California Safe Dispensing Act4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023. 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section. 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
13291
13392 Article 12.5. California Safe Dispensing Act
13493
13594 Article 12.5. California Safe Dispensing Act
13695
13796 4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.(b) This article shall become operative on June 30, 2023.
13897
13998
14099
141100 4178. (a) This article shall be known, and may be cited, as the California Safe Dispensing Act.
142101
143102 (b) This article shall become operative on June 30, 2023.
144103
145-4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).(A)(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.(B)(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.(c)(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d)(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs. (e)(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f)(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g)(h) The board may adopt regulations to carry out this article.(h)(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i)(j) Section 4321 shall not apply to a violation of this section.
104+4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:(1) Dispense the controlled substance in a lockable vial.(2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.(2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:(A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.(C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.(2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.(3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.(B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.(C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:(A) The failure of any lockable vial to prevent unauthorized access.(B) A patient not being able to access medication in a lockable vial.(2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.(g) The board may adopt regulations to carry out this article.(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.(2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.(i) Section 4321 shall not apply to a violation of this section.
146105
147106
148107
149108 4178.1. (a) As used in this article, lockable vial means a prescription locking vial that qualifies as a safe storage product as defined in paragraph (2) of subdivision (a) of Section 4106.5 that is made of materials classified as generally recognized as safe under Title 21 of the Code of Federal Regulations and meets the applicable standards specified in Part 1700 of Title 16 of the Code of Federal Regulations.
150109
151-(b) Except as provided in subdivision (c), (d), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:
110+(b) Except as provided in subdivision (c), a pharmacist who dispenses in solid oral dosage form a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act (21 U.S.C. Sec. 801 et seq.) shall do all of the following:
152111
153112 (1) Dispense the controlled substance in a lockable vial.
154113
155114 (2) Provide a copy of the Opioid Factsheet for Patients published by the federal Centers for Disease Control and Prevention.
156115
157-(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e). (f).
158-
159-(A)
116+(3)If the lockable vial uses an alphanumeric passcode or other code, include the code in any patient notes in the database or other system used by the pharmacy in the dispensing of prescription drugs.
160117
161118
162119
163-(c) (1) Except as provided in subparagraph (B), paragraph (2), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code. code for the lockable vial.
120+(3) Provide the patient with information regarding the online assistance or toll-free telephone number made available by the vendor providing the lockable vial pursuant to subdivision (e).
164121
165-(B)
122+(A) Except as provided in subparagraph (B), a patient, the patients parent or legal guardian if the patient is a minor or otherwise unable to authorize medical care, or the conservator of the patient if the conservator has been given the power to make health care decisions for the patient, shall choose the code.
166123
124+(B) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code.
167125
168-
169-(2) In the case of medications prescribed to a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, the minor shall choose the code. code for the lockable vial.
170-
171-(c)
172-
173-
174-
175-(d) (1) A pharmacist shall not dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, to the pharmacists knowledge, would have difficulty opening the lockable vial.
126+(c) (1) A pharmacist shall not dispense a controlled substance in Schedule II of the federal Controlled Substances Act in a lockable vial directly to a patient who, because of a physical or mental condition, would have difficulty opening the lockable vial.
176127
177128 (2) A pharmacist is not required to dispense a controlled substance in Schedule II or Schedule IIN of the federal Controlled Substances Act in a lockable vial in any of the following circumstances:
178129
179130 (A) The prescription, dispensation, and administration of the controlled substance occurs in a hospital or other inpatient care facility.
180131
181-(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) (c) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.
132+(B) The patient, including a patient who is a minor who may consent to services specified in Chapter 3 (commencing with Section 6920) of Part 4 of Division 11 of the Family Code, or the patients representative who is authorized pursuant to paragraph (3) of subdivision (b) to choose the code for the lockable vial requests to their prescriber or the pharmacist that the patients medication not be dispensed in a lockable vial.
182133
183134 (C) The prescriber indicated on the prescription that the patient requested not to receive their medication in a lockable vial.
184135
185-(d)
186-
187-
188-
189-(e) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.
136+(d) (1) The manufacturer of a controlled substance covered by this section shall reimburse the pharmacy within 30 days of receiving a claim for the acquisition cost of lockable vials used by the pharmacy to dispense controlled substances covered by this section. The acquisition cost shall not exceed two dollars ($2) per lockable vial.
190137
191138 (2) The manufacturer of a controlled substance covered by this section shall compensate the pharmacy within 30 days of receiving the claim for dispensing costs and services rendered, including any patient consultation and instruction or any other professional services rendered to comply with this section. The board shall establish a reasonable rate of compensation that is not less than two dollars and fifty cents ($2.50) per lockable vial. A pharmacy technician or other pharmacy staff may complete all tasks in this section that are not otherwise prohibited by law.
192139
193140 (3) (A) A manufacturer of a controlled substance that fails to reimburse a pharmacy within the time period and for the amount specified in this subdivision is liable for a civil penalty of one thousand dollars ($1,000) per day for each day the manufacturer is delinquent in reimbursing the pharmacy.
194141
195142 (B) The civil penalty shall be assessed and recovered in a civil action brought by the board in the name of the people of the State of California.
196143
197144 (C) Assessment of a civil penalty, at the request of the manufacturer of the controlled substance that was assessed the penalty, may be reviewed on appeal and the penalty may be reduced or waived for good cause.
198145
199-(4) By October 1, 2023, the board shall establish reasonable minimum and maximum amounts of reimbursement that include the cost of the vial and services rendered and dispensing costs.
146+(e) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.
200147
201-(e)
202-
203-
204-
205-(f) Any vendor that contracts with a pharmacy to provide a lockable vial shall make available at all times assistance online or through a toll-free telephone number for patient use.
206-
207-(f)
208-
209-
210-
211-(g) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:
148+(f) (1) A prescriber, or the prescribers professional corporation or other business entity, or a pharmacist or pharmacy corporation, who prescribes or dispenses a controlled substance dispensed in a lockable vial shall not be liable for any adverse consequences that result from either of the following:
212149
213150 (A) The failure of any lockable vial to prevent unauthorized access.
214151
215152 (B) A patient not being able to access medication in a lockable vial.
216153
217154 (2) This subdivision does not affect a persons liability under existing law for damages caused by defective products, or as a result of willful or wanton misconduct, recklessness, or gross negligence.
218155
219-(g)
156+(g) The board may adopt regulations to carry out this article.
220157
221-
222-
223-(h) The board may adopt regulations to carry out this article.
224-
225-(h)
226-
227-
228-
229-(i) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.
158+(h) (1) The board shall assess a fine in an amount to be determined by the board for a violation of this section by a pharmacist.
230159
231160 (2) The board may choose not to take administrative action against a pharmacy if it determines that compliance with this section would create a financial hardship on the pharmacy or that the pharmacy was temporarily out of stock of lockable vials after taking reasonable steps to ensure an adequate supply for all dispensations of Schedule II or Schedule IIN controlled substances.
232161
233-(i)
234-
235-
236-
237-(j) Section 4321 shall not apply to a violation of this section.
162+(i) Section 4321 shall not apply to a violation of this section.
238163
239164 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.
240165
241166
242167
243168 4178.2. This article does not apply to correctional pharmacies, correctional clinics, or patients of the Department of Corrections and Rehabilitation.